Infant Bacterial Therapeutics AB - ESG Rating & Company Profile powered by AI
If you work at Infant Bacterial Therapeutics AB and you would like to use your Sustainability rating, please contact us. Detailed ESG analysis of Infant Bacterial Therapeutics AB are accessed by signing up for free. This article includes a questions and answers table about Infant Bacterial Therapeutics AB.
Infant Bacterial Therapeutics AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.7; made up of an environmental score of 5.3, social score of 4.8 and governance score of 4.0.
4.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 816 | Pliant Therapeutics Inc | 4.8 | High |
| 816 | Voyager Therapeutics Inc | 4.8 | High |
| 837 | Infant Bacterial Therapeutics AB | 4.7 | High |
| 837 | Bio Rad Laboratories Inc | 4.7 | High |
| 837 | Katakura Industries Co Ltd | 4.7 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Infant Bacterial Therapeutics AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose current and historical energy intensity?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB report the average age of the workforce?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose cybersecurity risks?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB offer flexible work?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB conduct supply chain audits?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose water use targets?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB have careers partnerships with academic institutions?
Sign up for free to unlockDid Infant Bacterial Therapeutics AB have a product recall in the last two years?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose incidents of discrimination?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Infant Bacterial Therapeutics AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose parental leave metrics?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Infant Bacterial Therapeutics AB involved in embryonic stem cell research?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose its waste policy?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB report according to TCFD requirements?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose energy use targets?
Sign up for free to unlockDoes Infant Bacterial Therapeutics AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Infant Bacterial Therapeutics AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Infant Bacterial Therapeutics AB
These potential risks are based on the size, segment and geographies of the company.
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.